ClinicalTrials.gg

Liver Cirrhosis, Biliary clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 214 studies for Liver Cirrhosis, Biliary across more than 10 countries. 48 are recruiting or about to start. 180 of them are mainly about Liver Cirrhosis, Biliary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
96
Recruiting
34
Status unknown
25
Terminated
22
Active, not recruiting
16
Not yet recruiting
11

Phase

Phase 2
63
Phase 3
44
Phase 1
26
Phase 4
15
Early Phase 1
4

Where

United States
83
China
52
United Kingdom
41
Canada
39
Germany
32
Spain
32

Who develops what

Add Liver Cirrhosis, Biliary to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 6 companies, 7 with this as their studies’ main aim; 4 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Gilead Sciences, GlaxoSmithKline and Ipsen here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Ursodeoxycholic AcidRecent, limited
Evidence
  • NCT05450887 · Sino Biopharmaceutical Limited · Phase 3 · background · “UDCA” · registered Jul 2022
  • NCT04956328 · Sino Biopharmaceutical Limited · Phase 3 · background · “UDCA” · registered Jul 2021
  • NCT01904058 · Mirum Pharmaceuticals, Inc. · Phase 2 · background · “Ursodeoxycholic Acid” · registered Jul 2013
  • NCT01899703 · GlaxoSmithKline · Phase 2 · background · “Ursodeoxycholic acid” · registered Jul 2013
  • NCT00550862 · Alfasigma S.p.A. · Phase 2 · background · “Ursodeoxycholic Acid (URSO)” · registered Oct 2007
Daewoong Pharmaceutical Co. LTD.50% of its industry studiesUS: off-patent, 13 generics marketed11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
elifibranorApproved: US 2024 · EU 2024☆ Track3 live phase-3 studies: NCT04526665, NCT06016842, NCT06730061Ipsen
saroglitazarPhase 4 trial recorded☆ Track3 live phase-3 studies: NCT07424677, NCT07216235, NCT06427395Zydus Lifesciences Limited
linerixibatApproved: US 2026 · EU 2026☆ Track2 live phase-3 studies: NCT07860710, NCT04167358GlaxoSmithKline
seladelparApproved: US 2024☆ Track2 live phase-3 studies: NCT06051617, NCT03301506Gilead Sciences

The 4 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 17 Dec 2026 est.elifibranor · Ipsen · Phase 3 main aimNCT06730061 A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) — primary endpoint: Percentage of participants with Alkaline phosphatase (ALP) <1.67x ULN, ALP decrease ≥15% and Total Bilirubin (TB) ≤ ULN · 18 enrolled
  • 1 Mar 2027 est.nalmefene · tharimmune inc · Phase 2 named, not the main aimNCT06733519 TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis — primary endpoint: The primary objective is to investigate the safety and tolerability of repeat doses of TH104 · 40 enrolled
  • 18 Apr 2027 est.saroglitazar · Zydus Lifesciences Limited · Phase 3 main aimNCT06427395 Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis — primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 · 102 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Liver Cirrhosis, Biliary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 5 · Reverse transcriptase inhibitors 3

Coming up

14studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger. 3 (9%) take children under 18. 1 (3%) are for women only and 0 (0%) for men only; 4 (12%) take healthy volunteers.

Recruiting studies that take each age, of 34
AgeWomenMen
103 (9%)2 (6%)
1833 (97%)32 (94%)
3034 (100%)33 (97%)
4034 (100%)33 (97%)
5034 (100%)33 (97%)
6534 (100%)33 (97%)
7531 (91%)30 (88%)
8519 (56%)18 (53%)

Across all 214 studies, recruiting or not: 45% stop at 75 or younger and 9% at 65; 6% take children; 2% are for women only and 1% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Liver Cirrhosis, Biliary studies take

Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 16 mo2–24 · 15 studies——
Phase 223 mo18–34 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 214. Browse all 214 → or search them.